MEway Pharma
Combined Solution for Nebulization and Inhalation
Company Overview
Snapshot
Founded in January 2014 by Eran Eilat, Joshua Altman, and Moshe Tshuva, MEway Pharma operates with 1–10 employees. The company has raised $1M across one funding round. In January 2015, MEway Pharma secured Seed funding from Sanara Ventures.
Business overview
MEway Pharma develops integrated solutions for nebulization and inhalation to enhance pulmonary drug delivery. The company's core product, the UltraFlow Nebulizer, is a handheld device designed for fine particle emission, rapid flow rate, and breath-actuated mechanisms, aiming to improve treatment efficacy and reduce duration. MEway Pharma operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Pharma & Medical Biotechnology industries with its drug delivery technologies.
Log in to access full profile ›Company Intelligence Q&A
- What is MEway Pharma's primary focus?
- MEway Pharma focuses on developing combined solutions for nebulization and inhalation to improve the efficiency of pulmonary drug delivery.
- Who founded MEway Pharma?
- MEway Pharma was founded by Eran Eilat, Joshua Altman, and Moshe Tshuva in January 2014.
- What is the UltraFlow Nebulizer?
- The UltraFlow Nebulizer is a handheld device developed by MEway Pharma that combines fine particle emission, rapid flow rate, and a breath-actuated mechanism to enhance pulmonary drug delivery.
- When did MEway Pharma cease operations?
- MEway Pharma ceased to operate in September 2022.
- Which investor participated in MEway Pharma's Seed funding round?
- In January 2015, MEway Pharma secured Seed funding from Sanara Ventures, an Israeli venture firm.